Heron Therapeutics Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Heron Therapeutics Inc trades at $0.34 (market cap $61.47M), while ZIM Integrated Shipping Services Ltd trades at $25.24 (market cap $2.96B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 48.2× Heron Therapeutics Inc's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | ZIM | |
|---|---|---|
Market Cap | $61.47M | $2.96B |
Sector | Health | Industrials |
52-Week High | $1.49 | $29.27 |
52-Week Low | $0.32 | $12.44 |
Enterprise Value | $168.21M | $6.81B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
ZIM trades at $25.29, up 0.32% on the day, amid a bearish technical outlook and mixed earnings performance. The stock shows weak profitability with a net margin of 1.56% and declining revenue projections for 2026. Recent news highlights uncertainty around a potential merger with Hapag-Lloyd and upcoming Q2 2026 earnings, with analyst sentiment evenly split between hold and sell recommendations.
The outlook for ZIM is cautious, with risks from merger uncertainty and operational pressures outweighing its low valuation multiples. Investment opportunity hinges on successful execution and merger approval, but current fundamentals and bearish technicals suggest limited near-term upside amid high volatility.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →